(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 July 2011 (07.07.2011)

PCT

(10) International Publication Number
WO 2011/082285 A1

(51) International Patent Classification:
C40B 30/04 (2006.01)

(21) International Application Number:
PCT/US2010/062473

(22) International Filing Date:
30 December 2010 (30.12.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/335,043 30 December 2009 (30.12.2009) US

(71) Applicant *(for all designated States except US)*: **AVILA THERAPEUTICS, INC.** [US/US]; 100 Beaver Street, Waltham, Massachusetts 02453 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **PETTER, Russell C.** [US/US]; 22 Robinwood Lane, Stow, Massachusetts 01775 (US). **JEWELL, Charles F.** [US/US]; 10130 Cape Ann Drive, Columbia, Maryland 21046 (US). **LEE, Kwangho** [KR/US]; 22 Middlesex Circle, #7, Waltham, Massachusetts 02452 (US). **MEDIKONDA, Aravind Prasad** [IN/US]; 846 Massachusetts Avenue, #4C, Arlington, Massachusetts 02474 (US). **NIU, Deqiang** [US/US]; 162 Lowell Street, Lexington, Massachusetts 02420 (US). **QIAO, Lixin** [US/US]; 49 Blanchard Street, Andover, Massachusetts 01810 (US). **SINGH, Juswinder** [GB/US]; 94 Heritage Avenue, Ashland, Massachusetts 01721 (US). **ZHU, Zhendong** [US/US]; 8 Nipmuck Drive, Westborough, Massachusetts 01581 (US).

(74) Agents: **TUSCAN, Michael S.** et al.; Cooley LLP, 777 6th St, NW, Suite 1100, Washington, District of Columbia 20001 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) Title: LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN

X-ray co-crystal structure (2JK7) shows key lysines in XIAP proximal to bound Smac-mimetic ligand




FIGURE 1

(57) Abstract: The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.

WO 2011/082285 A1

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*